What is a Form 483?
Form 483 is the document the US Food and Drug Administration (FDA) uses to record objectionable conditions identified during an inspection. The agency issues it at the close of an inspection of any facility involved in the manufacturing, processing, packing, or holding of food, drugs, medical devices, or biological products. The FDA inspects under the authority of Section 704 of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Form 483 is also referred to as “Inspectional Observations” or simply “the 483”.
The 483 contains information on observations made by the FDA representatives during the inspection of the facility. It includes the FDA district issuing office that performed the inspection, the date(s) of inspection, the name and address of the inspected facility, the FDA Establishment Identifier (FEI) number, and the name and title of the person to whom it is issued.
The observations on it are the views of the FDA investigators present and may be subject to review by other FDA personnel. They are not the agency's final determination of compliance.
What's on From 483, and what isn't
A 483 lists significant observations the investigator believes may indicate a violation of the FD&C Act or related regulations. It is not an exhaustive list of every issue at a site. Observations of questionable significance are not listed; instead they are discussed verbally with management so that the company understands how an uncorrected problem might escalate.
The form has space for the investigator to annotate whether an observation has been corrected, or is being addressed, by the close of the inspection.
The FDA also inspects facilities that produce human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR 1271 Subpart F. Observations from these inspections are also captured on a Form 483.
The FDA's authority is limited to the United States, but the agency inspects foreign facilities that form part of the US supply chain. Foreign 483s are issued in the same way, and the form is always written in English.
Common causes of a Form 483 observation
An FDA 483 observation can be very expensive, resulting in thousands or even millions of dollars in costs for some companies. If the issues are systemic, the Form 483 observation can trigger training, process redesign, equipment changes, process implementation, and quality system updates.
Handling these problems all at the same time can be expensive and disruptive to a company. It’s far better to anticipate issues that might result in a Form 483 and build processes to avoid that scenario. The most common causes of a 483 observation are:
- Procedures not fully followed.
- Failure to thoroughly investigate discrepancies, deviations, or out-of-specification results (per 21 CFR 211.192).
- Absence of written procedures where they are required
- Inadequate training of personnel.
- Inadequate controls over processes, materials, equipment, or data.
Taking the time to be diligent with written procedures can help prevent a company from receiving a 483. SOPs (standard operating procedures) are required for document control, risk management, design controls, and many other aspects of device manufacturing.
Regulators want evidence that a company has outlined a way to handle these fundamental processes, otherwise they may issue a Form 483 observation. If a company does receive a Form 483, there are a few rules around responding that should be considered.
How to respond to a Form 483
The FDA expects a written response within 15 business days of receiving the Form 483. This is the headline recommendation in the FDA's March 2026 draft guidance for industry, Responding to FDA Form 483 Observations at the conclusion of a Drug CGMP Inspection.
A response is not legally compulsory. But if a response arrives after the 15 business day window, the FDA will not ordinarily delay regulatory action, such as issuing a Warning Letter, while it reviews the response. A late or weak response narrows the company's options.
A strong 483 response is structured, evidence-based, and signed by someone with the authority to act. Specifically, the FDA recommends that the response include:
- A table of contents and a copy of the Form 483 itself.
- The identity of the response preparer, including their relationship to the establishment if external.
- An executive summary of all remediation activities, with a table mapping each observation to its CAPA, target date, and current progress.
- A patient- and product-focused risk assessment for inventory and distributed drugs still within expiry, including any effects on safety, identity, strength, quality, and purity.
- For each observation: a detailed investigation report with scope, methodology, the affected drugs and lot numbers, the identified root cause(s), any related systemic issues, the CAPA plan, and the effectiveness evaluation.
- A CAPA plan that covers immediate corrective actions, planned actions, preventive actions, and interim measures, all commensurate with the level of risk.
- A communication plan for ongoing remediation, with milestone deliverables and follow-up reports.
Related observations can be grouped by topic or system (for example: quality, production, facilities and equipment, packaging and labelling, materials, laboratory control). Each observation must still be individually numbered and listed in the table of contents.
The response should be signed by a person in executive management who allocates resources and has the authority to implement commitments. The site head or the head of the quality unit may also opt to sign.
When observations involve data integrity findings, the FDA recommends engaging a cGMP consultant for additional insight and to support the CAPA plan.
All correspondence should be submitted in English. Documents originally in another language should come with a verified English translation, accompanied by the translator's name, address, and a brief statement of qualifications.
What if you disagree with an observation?
Scientific or technical disagreements should first be raised with the FDA representatives during the inspection. If the disagreement is not resolved before the Form 483 is issued, the FDA recommends addressing it in the 483 response itself. The response should describe the contested facts and provide scientific data and supporting information so the agency can evaluate the issue.
If the issue cannot be resolved through the 483 response, the company can use the formal two-tiered dispute resolution process described in the FDA guidance Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP. Companies can also raise concerns with the FDA Ombudsman or the office directing the inspection.
Note that the "30 calendar day" timeline often associated with formal dispute resolution refers to the FDA's response goal, not a deadline for the company to file.
Key takeaway
- A Form 483 is the FDA's record of objectionable conditions found during an inspection. It is not a final compliance determination, but it is a serious signal that the agency expects to be addressed.
- The recipient should respond in writing within 15 business days. The response should include an executive summary, a patient- and product-focused risk assessment, an investigation report, a CAPA plan with effectiveness evaluation, and a communication plan for follow-up. It should be signed by someone in executive management with authority to commit resources.
- Related observations can be grouped by topic or system, but each must still be individually numbered.
- Disagreements should be raised in the response itself, with data, before any escalation to formal dispute resolution.
Summary
Form 483 is a crucial document used by the FDA to document and communicate concerns discovered during inspections of facilities related to the manufacturing, processing, packing, or holding of food, drugs, medical devices, or biological products in the United States. It provides important information for the recipient to address the concerns and improve compliance. The recipient should respond to the FDA within 15 business days, and the response should be comprehensive, well-reasoned, well-documented, and timely, addressing each observation individually.
